Disclosed is a multimeric fusion protein and a method for producing the multimeric fusion protein. The method includes expressing in an mammalian cell a nucleic acid coding for an amino acid sequence comprising, in an N-terminal to C-terminal direction, a signal peptide, (optionally) an antigenic peptide, a CH3 domain of human IgG.sub.1, a (G-P-P).sub.10 collagen-like domain, and a TNF ligand superfamily extracellular domain, the extracellular domain being devoid of a coiled-coil trimerization motif, and allowing the polypeptides expressed in the mammalian cell from the nucleic acid to at least one of trimerize and hexamerize into one or more multimeric fusion proteins.

Disclosed is a multimeric fusion protein and a method for producing the multimeric fusion protein. The method includes expressing in an mammalian cell a nucleic acid coding for an amino acid sequence comprising, in an N-terminal to C-terminal direction, a signal peptide, (optionally) an antigenic peptide, a CH3 domain of human IgG.sub.1, a (G-P-P).sub.10 collagen-like domain, and a TNF ligand superfamily extracellular domain, the extracellular domain being devoid of a coiled-coil trimerization motif, and allowing the polypeptides expressed in the mammalian cell from the nucleic acid to at least one of trimerize and hexamerize into one or more multimeric fusion proteins.

The present application provides formulations of enhanced antigen presenting cells (enhanced APCs), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

The present application provides formulations of enhanced antigen presenting cells (enhanced APCs), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The present disclosure provides, inter alia, compositions, cell populations and pharmaceutical compositions and methods useful for the treatment of inflammatory diseases or disorders. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via treatment with a CD44 ligand for a period of time sufficient to prime the cells to produce elevated levels of one or more anti-inflammatory or immunomodulatory molecules relative to a native populations of CD44.sup.+ cells. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via a treatment that is effective to target cells to sites of inflammation.

The present disclosure provides, inter alia, compositions, cell populations and pharmaceutical compositions and methods useful for the treatment of inflammatory diseases or disorders. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via treatment with a CD44 ligand for a period of time sufficient to prime the cells to produce elevated levels of one or more anti-inflammatory or immunomodulatory molecules relative to a native populations of CD44.sup.+ cells. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via a treatment that is effective to target cells to sites of inflammation.

This invention relates to compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the invention relates to antigenic RAS peptide fragments and T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

This invention relates to compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the invention relates to antigenic RAS peptide fragments and T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.